Lipvas
Lipvas is Cipla’s atorvastatin 10/20/40 mg tablets — the most-used statin globally. Originally Parke-Davis/Pfizer Lipitor (1996). Lipophilic, CYP3A4-cleared. Evidence: CARDS (primary prevention in diabetes), ASCOT-LLA (hypertensive dyslipidaemia), SPARCL (post-stroke), TNT (intensive secondary prevention). Dose range 10-80 mg, 40-80 mg = high-intensity. Reduces LDL-C by 50-55%. Grapefruit juice, CYP3A4 inhibitors substantially raise levels.
✓ Lääketieteellinen tarkistus Morgan Ellis — Farmasian tutkija · 8 vuoden kokemus · Viimeisin arvio: toukokuu 2026
⚡ Quick Answer — What is Lipvas?
Lipvas on 10 / 20 / 40 mg atorvastatin tablet from Cipla — a high-intensity HMG-CoA reductase inhibitor (statin), lipophilic. Statins reduce cardiovascular events by 20-30% per mmol/L LDL-cholesterol reduction across primary prevention, secondary prevention, diabetes, and post-stroke populations. Atorvastatin was introduced by Parke-Davis/Pfizer in 1996 as Lipitor — the best-selling drug of all time at its peak ($12.5 billion/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA/ACC 2018 lipid guidelines. Potency: atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Typical dose: once daily, evening (for short-half-life statins) or any time for atorvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.
📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.
Miksi tilata MedsBasesta
Geneeriset lääkkeemme on hankittu WHO-GMP sertifioiduilta valmistajilta ja toimitettu maailmanlaajuisesti hienotunteisessa, neutraalissa pakkauksessa — lääkkeen nimeä ei ole pakkauksen ulkopuolella. Korttimaksut käsitellään säädeltyjen maksunvälittäjien kautta (tilisiirtojen kuvaukset sisältävät säädellyn korttimaksun käsittelijän — ei koskaan “MedsBase” tai lääkkeen nimeä). Kryptovaluutat ja SEPA-pankkisiirrot hyväksytään myös. Jokainen tilaus on turvattu meidän Reshipment Assurance Policy -takuuohjelmalla.
What Is Lipvas?
Lipvas is an oral 10 / 20 / 40 mg atorvastatin tablet from Cipla, supplied in 30-180 tablets. Atorvastatin was introduced by Parke-Davis/Pfizer in 1996 as Lipitor — the best-selling drug of all time at its peak ($12.5 billion/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA/ACC 2018 lipid guidelines.
How Atorvastatin Works
Atorvastatin inhibits HMG-CoA-reduktaasille, the rate-limiting enzyme of hepatic cholesterol biosynthesis. Downstream:
- Reduced intracellular cholesterol in hepatocytes — triggers sterol-regulatory element binding protein (SREBP) activation and upregulation of LDL-receptor expression on the hepatocyte surface
- Increased clearance of circulating LDL-C — the primary LDL-lowering mechanism
- Modest triglyceride reduction (10-20%) and modest HDL rise (5-10%)
- Pleiotropic effects beyond LDL-lowering — reduced vascular inflammation (hs-CRP drop), improved endothelial function, plaque stabilisation, reduced platelet reactivity. The magnitude of the clinical benefit across trials exceeds what is explained by LDL-C change alone.
Lipvas Dosage
Primary prevention (no prior CV event): start 10-20 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk >7.5%, moderate-intensity (20-40 mg) is typical.
Secondary prevention (prior MI, stroke, PAD, or diabetic CVD): high-intensity therapy — 40-80 mg once daily. Target LDL-C <1.8 mmol/L (<70 mg/dL) per 2019 ESC and <1.4 mmol/L (<55 mg/dL) for very-high-risk ASCVD per 2021 ESC update.
Familial hypercholesterolaemia: maximum-tolerated statin (usually 80 mg) often combined with ezetimibe 10 mg and/or PCSK9 inhibitor (alirocumab/evolocumab/inclisiran) to achieve guideline targets.
Annostelu: once daily with or without food. Evening dosing is no longer required for atorvastatin (long half-life); any consistent time of day is fine.
Seuranta:
- Alkutilanne: full lipid panel, LFTs (ALT), creatine kinase (CK), HbA1c or fasting glucose, creatinine, thyroid-stimulating hormone (TSH) if not recently checked.
- 4-12 viikkoa: repeat lipids to assess response. Expect atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Dose-escalate if target not met.
- Vuosittain: lipids, LFTs (unless symptomatic). CK only on muscle complaints, not routinely.
- Keskeytä ja tutki: CK >10× ULN, ALT >3× ULN and rising, persistent unexplained muscle pain with CK >5× ULN, rhabdomyolysis (dark urine, profound weakness).
Evidence for Atorvastatin
CARDS (2004) — atorvastatin 10 mg in 2,838 type 2 diabetics without overt CVD reduced major CV events by 37% (primary prevention in diabetes). ASCOT-LLA (2003) — atorvastatin 10 mg in 10,305 hypertensives reduced CV events by 36%. TNT (2005) — 80 mg vs 10 mg in stable CAD; high-dose reduced events by 22%. PROVE-IT (2004) — atorvastatin 80 mg vs pravastatin 40 mg post-ACS; atorvastatin superior. SPARCL (2006) — atorvastatin 80 mg after stroke/TIA reduced recurrent stroke by 16%.
Hyväksytyt ja tutkimusnäyttöön perustuvat käyttöalueet
- Primary and secondary prevention of cardiovascular disease in patients with dyslipidaemia
- Type 2 diabetes (CARDS) even with “normal” LDL
- Post-stroke secondary prevention (SPARCL)
- Familial hypercholesterolaemia (80 mg; often requires combination with ezetimibe or PCSK9 inhibitor)
Practical Considerations
Grapefruit juice interacts — inhibits intestinal CYP3A4, raising atorvastatin levels 2-3 fold. Small amounts (one glass, once) usually OK; regular daily grapefruit should be avoided. Voimakkaat CYP3A4-estäjät (clarithromycin, ritonavir, ketoconazole) substantially raise atorvastatin levels and myopathy risk.
Haittavaikutukset
Yleiset (>1%):
- Myalgia (muscle pain) — bothersome in 5-10% of users; confirmed statin-associated muscle symptoms with CK rise in 0.1-1%. High nocebo component: SAMSON trial (2020) showed no difference between statin and placebo in double-blind n-of-1 crossovers in many “statin-intolerant” patients.
- Lieviä transaminaasien nousuja — 3% have ALT rise below 3× ULN; usually transient and does not require dose change.
- New-onset diabetes — absolute excess ~0.2 per 100 patient-years, mostly in prediabetic patients. CV benefit far exceeds diabetes risk.
- Headache, dyspepsia, nausea
- Erektiohäiriö (uncommon; mechanism unclear)
- Sleep disturbance, cognitive fog (reported but not consistent in RCTs)
Epätyypillisiä mutta kliinisesti merkittäviä:
- Rhabdomyolyysi (<1 per 10,000 patient-years) — severe muscle breakdown, renal failure risk. Stop immediately on dark urine + profound weakness + CK >10× ULN.
- Immuunivälitteinen nekrotoiva myopatia — rare persistent myopathy that continues after stopping statin; anti-HMGCR antibody mediated. Needs immunosuppressive treatment.
- Severe transaminitis / drug-induced liver injury — rare; stop if ALT >3× ULN with symptoms or rising trajectory.
- Perifeerinen neuropatia (harvinainen)
Käyttökiellot
- Raskaus ja imetys — statins are contraindicated; cholesterol is required for fetal neurodevelopment.
- Aktiivinen maksasairaus or unexplained persistent ALT >3× ULN.
- Prior rhabdomyolysis or severe statin-intolerance confirmed in double-blind rechallenge.
- Samanaikaiset voimakkaat CYP3A4-estäjät (for atorvastatin): clarithromycin, itraconazole, ritonavir — hold statin or switch to rosuvastatin/pravastatin.
- Hypersensitivity to the statin.
Lääkeaineenvaihdunta
- Voimakkaat CYP3A4-estäjät — KRIITTINEN. Clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, cobicistat, ciclosporin — raise atorvastatin levels 2-10 fold. Hold statin during short antibiotic courses; switch to rosuvastatin or pravastatin for long-term CYP3A4 inhibitor co-therapy.
- Greippimehu — avoid regular daily consumption with atorvastatin (2-3 fold interaction).
- Fibrates (gemfibrozil, fenofibrate) — additive myopathy risk. Gemfibrozil is the worst; fenofibrate is the preferred fibrate for combination. Reserve combinations for specialist dyslipidaemia care.
- Niacin high-dose — additive myopathy risk. Low-dose niacin (1-2 g) usually tolerated.
- Varfariini — small INR rise with statin initiation; check INR 1 week after starting. Not a contraindication.
- Digoksiini — small digoxin level rise with atorvastatin (P-glycoprotein); usually not clinically significant.
- Alkoholi — heavy intake raises liver injury risk. Moderate intake is acceptable.
Säilytys
Store Lipvas below 25°C in the original blister pack. Keep out of reach of children.
Usein Kysytyt Kysymykset
Do I have to take Lipvas at night?
No — atorvastatin has a 20-30-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The “take statins at night” rule comes from short-half-life statins (simvastatin, lovastatin).
What if I get muscle aches on Lipvas?
Common and rarely dangerous. Check creatine kinase (CK). If CK is normal, the pains are usually not statin-related — the SAMSON trial (2020) showed most “statin-intolerant” patients had equal aches on placebo in double-blind crossover. Options: continue statin with vitamin D supplementation (if deficient), try coenzyme Q10 (weak evidence but low-risk), switch statin (rosuvastatin has lower muscle-symptom rate than simvastatin and atorvastatin in some trials), lower the dose, or adopt alternate-day dosing. Only stop if CK >10× ULN, symptoms are disabling, or there is objective weakness.
Will Lipvas give me diabetes?
Statins cause a small excess of new-onset diabetes — approximately 1 extra diabetes case per 1,000 people per year, mostly in those already at high diabetes risk (overweight, prediabetes, family history). The same treatment prevents roughly 5-10 cardiovascular events per 1,000 people per year in the same populations — so the net benefit is strongly positive. Do not stop a statin because of diabetes risk alone.
Can I take Lipvas with grapefruit juice?
Occasional small amounts of grapefruit juice (one glass) are usually fine. Daily consumption substantially raises atorvastatin levels (2-3 fold via intestinal CYP3A4 inhibition) and increases myopathy risk. If you drink grapefruit juice regularly, switch to rosuvastatin or pravastatin, which have minimal grapefruit interaction.
How long will I need to take Lipvas?
Indefinitely, in almost all cases. Stopping a statin causes LDL-C to rebound within weeks and cardiovascular protection is lost within months. Statins are lifelong preventive therapy for atherosclerotic disease, not a short course.
Can I take Lipvas in pregnancy?
No — statins are contraindicated in pregnancy and breastfeeding. Cholesterol is required for fetal neurodevelopment; statins cross the placenta. Stop the statin before planned pregnancy; if pregnancy is unplanned, stop immediately and discuss risks with a specialist. Familial hypercholesterolaemia patients can usually safely defer statin therapy during pregnancy and breastfeeding.
Where can I buy Lipvas online?
You can buy Lipvas (atorvastatin 10 / 20 / 40 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Aiheeseen liittyvät sydän- ja verenpainelääkkeet
- Aldactone — Spironolactone (ei-selektiivinen MR-antagonisti)
- Amlode — Amlodipiini (CCB)
- Aten — Atenolol (beta-salpaaja)
- Cardace — Ramipriili (ACE-estäjä)
- Ecosprin — Aspiriini 75/150 mg
- Rosuline — Rosuvastatiini 5/10 mg
- Selaa kaikkia verenpainelääkkeitä
Miksi tilata MedsBasesta
Lipvas is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our Reshipment Assurance Policy -politiikkamme piiriin. Korttimaksun tiliotteesi näyttää säännellyn maksunvälittäjän (säännelty korttimaksujen käsittelijä), ei koskaan “MedsBase” tai minkään lääkkeen nimeä.
Aiheeseen liittyvät vaihtoehdot
Muut tuotteet Krooniset sairaudet joita asiakkaat myös katsovat:
Lisää vaihtoehtoja korkean kolesterolitason hoidoissa
Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.
| Määrä | 30 tablettia, 60 tablettia, 90 tablettia, 180 tablettia |
|---|---|
| Srength | 10 mg, 20 mg, 40 mg |
Lipvas
Kysymykset ja vastaukset
Lipvas
Liittyvät tuotteet
Arvostelut
Ei vielä arvosteluja